Search

Erdafitinib

In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for … Erdafitinib is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the development of more personalized and precise

Cyproheptadine

[L32474] It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation[L32519] and its off-label use in the treatment of serotonin syndrome. … Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors.

(3E)-4-(1-METHYL-1H-INDOL-3-YL)BUT-3-EN-2-ONE

Mizolastine

Mizolastine is under investigation in clinical trial NCT01928316 (A Bioequivalence Study of Domestic (Made in China) and Imported Mizolastine Tablets in Healthy Volunteers).

Eszopiclone

This sets it apart from many other hypnotic sedatives, which are generally approved only for the relief of short-term (6-8 weeks) insomnia. Eszopiclone was initially approved by the FDA in 2004. … One major benefit of eszopiclone is that it is approved by the FDA for the long-term treatment of insomnia.